TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21865175

Group type: EXPERIMENTAL
Intervention: 7-valent PCV given at birth (newborn group)
Number of subjects: 300

Group type: COMPARATOR
Intervention: 7-valent PCV given at 6, 10, and 14 weeks (EPI group)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 7-valent PCV (both groups)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 7-valent PCV (newborn group)
Number of subjects: 300
Study: 19717691

Group type: EXPERIMENTAL
Intervention: Counselling including labelling with COPD plus nortriptyline for smoking cessation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Counselling excluding labelling with COPD plus nortriptyline for smoking cessation
Number of subjects: 205

Group type: COMPARATOR
Intervention: Care as usual for smoking cessation by the general practitioner without labelling with COPD
Number of subjects: 205
Study: 17352284

Group type: EXPERIMENTAL
Intervention: Antiresorptive agents (bisphosphonates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide (synthetic 1-34 parathormone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Strontium ranelate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D and calcium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin and raloxifene
Number of subjects: 0
Study: 15130978

Group type: EXPERIMENTAL
Intervention: Caregiver training in basic nursing and facilitation of personal care techniques
Number of subjects: 300

Group type: COMPARATOR
Intervention: No caregiver training
Number of subjects: 300
Study: 21547704

Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 38
Study: 9757381

Group type: EXPERIMENTAL
Intervention: Pravastatin therapy
Number of subjects: 1000
Study: 7886763

Group type: EXPERIMENTAL
Intervention: ELISA for anti-Brugia malayi IgG
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: ELISA for anti-Brugia malayi IgG4
Number of subjects: 1561

Group type: COMPARATOR
Intervention: Onchocerca gibsoni circulating antigen (Og4C3)
Number of subjects: 1561
Study: 3290156

Group type: EXPERIMENTAL
Intervention: Naproxen sodium 275 mg capsules per headache
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 31855009

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Depression plus Brief Motivational Interviewing (CBT-D + BMI)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy for Depression (CBT-D)
Number of subjects: 94
Study: 29794306

Group type: EXPERIMENTAL
Intervention: JNJ‐39439335 (2-50 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 28805601

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive pills (COC) containing 30 μg of EE and 3 mg of drospirenone for 12 consecutive cycles
Number of subjects: 200
Study: 26651333

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg or 200 μg)/vilanterol 25 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing asthma maintenance therapy
Number of subjects: 0
Study: 23725677

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cefazolin (2 g)
Number of subjects: 45
Study: 20948459

Group type: EXPERIMENTAL
Intervention: 20 mg triamcinolone acetonide anterior injection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: anterior injection followed by laser
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 40 mg triamcinolone acetonide posterior injection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: posterior injection followed by laser
Number of subjects: 96

Group type: COMPARATOR
Intervention: laser group
Number of subjects: 96
Study: 19088352

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet
Number of subjects: 210

Group type: COMPARATOR
Intervention: High-cereal fiber diet
Number of subjects: 210
Study: 17019555

Group type: EXPERIMENTAL
Intervention: Patient consent before randomisation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Relative assent
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Refusal of relative assent post-randomisation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: No relatives available for assent
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Unclear documentation on relative assent
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Survival of patients who did not provide consent prior to randomisation
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Retrospective informed consent after survival
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Refusal of retrospective informed consent
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Patients who did not regain mental competency
Number of subjects: 498
Study: 14983953

Group type: EXPERIMENTAL
Intervention: Screening with PSA (total PSA and free PSA) using Prostatus f/tPSA assay.
Number of subjects: 19946

Group type: EXPERIMENTAL
Intervention: Threshold tPSA of >= 4.0 ng/mL
Number of subjects: 19946

Group type: EXPERIMENTAL
Intervention: Threshold tPSA of >= 3.0 ng/mL combined with f/tPSA threshold of <= 18%
Number of subjects: 19946
Study: 14606149

Group type: EXPERIMENTAL
Intervention: Preoperative reservation of autoblood
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no preoperative reservation of autoblood)
Number of subjects: 143
Study: 10217588

Group type: EXPERIMENTAL
Intervention: FluMist (live attenuated cold adapted trivalent intranasal influenza vaccine)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intranasal placebo
Number of subjects: 100
Study: 7641902

Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (group B, n = 50)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Intrauterine insemination (group A, n = 50)
Number of subjects: 74
Study: 2491360

Group type: EXPERIMENTAL
Intervention: Omeprazole, 10 mg every morning
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Omeprazole, 20 mg every morning
Number of subjects: 270

Group type: COMPARATOR
Intervention: Ranitidine, 150 mg twice daily
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Omeprazole groups (both dosages)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Omeprazole and ranitidine groups
Number of subjects: 270
Study: 1095098

Group type: EXPERIMENTAL
Intervention: 200 rads daily five times weekly for four weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: 400 rads twice weekly for four weeks
Number of subjects: 30
Study: 28211107

Group type: EXPERIMENTAL
Intervention: Silver nitrate (95%) applied by healthcare professional (clinical group)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Silver nitrate (95%) self-applied (home group)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (clinical and home application)
Number of subjects: 113
Study: 25818492

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine
Number of subjects: 78

Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride with adrenaline
Number of subjects: 78
Study: 24089693

Group type: EXPERIMENTAL
Intervention: 1-week free nicotine replacement therapy (NRT) with behavioural counselling
Number of subjects: 562

Group type: COMPARATOR
Intervention: 2-week free nicotine replacement therapy (NRT) with behavioural counselling
Number of subjects: 562
Study: 21843494

Group type: EXPERIMENTAL
Intervention: Endoscopic drainage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Surgical drainage (operative pancreaticojejunostomy)
Number of subjects: 39
Study: 19289640

Group type: EXPERIMENTAL
Intervention: Warfarin (target INR of 2.5 to 3.0)
Number of subjects: 1587

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 1587

Group type: COMPARATOR
Intervention: Aspirin (162 mg once daily)
Number of subjects: 1587
Study: 17784893

Group type: EXPERIMENTAL
Intervention: TND Network (peer-led interactive version of TND)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Control classes (no intervention)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Towards No Drug Abuse (TND)
Number of subjects: 541
Study: 15271109

Group type: EXPERIMENTAL
Intervention: Intensive community nurse (CN)‐supported discharge program
Number of subjects: 157

Group type: COMPARATOR
Intervention: Control group (standard discharge care)
Number of subjects: 157
Study: 12171689

Group type: EXPERIMENTAL
Intervention: Oral supplement containing glucosamine, amino acids, minerals, and antioxidants
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (12 individuals who did not take the supplement)
Number of subjects: 53
Study: 9764631

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 7919326

Group type: EXPERIMENTAL
Intervention: Full dose (500 mL of plasma)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Half dose (250 mL of plasma diluted in 250 mL of 5% human serum albumin)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo (500 mL of 5% human serum albumin)
Number of subjects: 220
Study: 3277494

Group type: EXPERIMENTAL
Intervention: Calcium antagonists in combination with diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose diuretic and calcium blocker
Number of subjects: 0
Study: 31914324

Group type: EXPERIMENTAL
Intervention: Doxazosin (8 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study: 30772862

Group type: EXPERIMENTAL
Intervention: LuCApp in addition to standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 120
Study: 27307056

Group type: EXPERIMENTAL
Intervention: COMPAS program
Number of subjects: 635

Group type: EXPERIMENTAL
Intervention: ¡Cuídate! program
Number of subjects: 635

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 635
Study: 25931244

Group type: EXPERIMENTAL
Intervention: Ceftolozane-tazobactam (15 g every 8 hours for 7 days)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Levofloxacin (750 mg once daily for 7 days)
Number of subjects: 800
Study: 23412015

Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 563

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 563
Study: 21042870

Group type: EXPERIMENTAL
Intervention: S.S.GRIN‐HFA (n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (traditional S.S.GRIN intervention; n = 28)
Number of subjects: 55
Study: 19255022

Group type: EXPERIMENTAL
Intervention: Topiramate 100 mg/day
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Topiramate 50 mg/day
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 16728219

Group type: EXPERIMENTAL
Intervention: Multivessel PCI
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Single-vessel PCI
Number of subjects: 4744

Group type: EXPERIMENTAL
Intervention: Multivessel PCI with acute coronary syndrome
Number of subjects: 4744

Group type: COMPARATOR
Intervention: Single-vessel PCI with acute coronary syndrome
Number of subjects: 4744
Study: 14982764

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 17

Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 17
Study: 11917970

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 0
Study: 9234030

Group type: EXPERIMENTAL
Intervention: Consumption of beans twice or more per week
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Overall dietary intake
Number of subjects: 1010
Study: 7955823

Group type: EXPERIMENTAL
Intervention: Morning dosing of lomefloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening dosing of lomefloxacin
Number of subjects: 0
Study: 3117156

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29921613

Group type: EXPERIMENTAL
Intervention: Prostatic artery embolisation (PAE)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 103
Study: 28294430

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 2 weeks (IXEQ2W)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: 80 mg ixekizumab every 4 weeks (IXEQ4W)
Number of subjects: 2570

Group type: COMPARATOR
Intervention: 50 mg etanercept (ETN) twice weekly
Number of subjects: 2570

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 2570

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both schedules)
Number of subjects: 2570
Study: 26703684

Group type: EXPERIMENTAL
Intervention: ASUMA intervention
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 24660272

Group type: EXPERIMENTAL
Intervention: SRP combined with 1.7% hydrogen peroxide gel (Perio Gel) using custom trays
Number of subjects: 30

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 30
Study: 21980827

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 17555327

Group type: EXPERIMENTAL
Intervention: 0.8 g of DNJ-enriched powder (12 mg of DNJ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1.2 g of DNJ-enriched powder (18 mg of DNJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 g of DNJ-enriched powder (0 mg of DNJ)
Number of subjects: 0
Study: 15321435

Group type: COMPARATOR
Intervention: Intrathecal fentanyl 0 micrograms (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 5 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 10 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 15 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 20 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl 25 micrograms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All fentanyl groups (15, 20, 25 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All fentanyl groups (0, 5, 10 micrograms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All fentanyl groups
Number of subjects: 0
Study: 11136787

Group type: EXPERIMENTAL
Intervention: MAC treatment (macrolide therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (HIV‐1-infected persons without MAC bacteremia)
Number of subjects: 0
Study: 9638782

Group type: EXPERIMENTAL
Intervention: Orientation program (clinic tour, general information, Q&A session with oncology counselor)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 150
Study: 8209276

Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by radiotherapy (arm B)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Radiotherapy alone (arm A)
Number of subjects: 85
Study: 2563311

Group type: EXPERIMENTAL
Intervention: Prazosin (mean dose, 5 mg per day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Propranolol (mean dose, 133 mg per day)
Number of subjects: 23
Study: 31544432

Group type: EXPERIMENTAL
Intervention: Kirschner wire-fixation-cortical bone technique
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 40
Study: 29787743

Group type: EXPERIMENTAL
Intervention: Scvo2 < 70% at 6 hours in subjects with initial Scvo2 < 70%
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Scvo2 < 70% at 6 hours in subjects with initial Scvo2 ≥ 70%
Number of subjects: 1475
Study: 26838150

Group type: EXPERIMENTAL
Intervention: Live display of the dental operating microscope (DOM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tell‐Show‐Do (TSD) technique without DOM
Number of subjects: 90
Study: 24285635

Group type: EXPERIMENTAL
Intervention: Booklet + Pedometer (GB + P)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pedometer + Booklet (GP + B)
Number of subjects: 31
Study: 23065000

Group type: EXPERIMENTAL
Intervention: Fulvestrant 500 mg
Number of subjects: 205

Group type: COMPARATOR
Intervention: Anastrozole 1 mg
Number of subjects: 205
Study: 19967563

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (900 mg per day for 6 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (900 mg per day for 6 months)
Number of subjects: 25
Study: 17872903

Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 16109326

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 48 mg/min
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vitamin C (VITC) 18 mg/min
Number of subjects: 30
Study: 12601621

Group type: EXPERIMENTAL
Intervention: Weight loss (10 kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control weight maintenance
Number of subjects: 22
Study: 11082219

Group type: EXPERIMENTAL
Intervention: Bilateral ligation of the inferior thyroid artery (ITA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No ligation of the inferior thyroid artery (ITA)
Number of subjects: 48
Study: 8875514

Group type: EXPERIMENTAL
Intervention: Glutamine-supplemented total parenteral nutrition (GTPN) with 25 g crystalline L-glutamine per 24 h
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional total parenteral nutrition (CTPN)
Number of subjects: 38
Study: 1520230

Group type: EXPERIMENTAL
Intervention: Nondirective psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behaviour therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relaxation/placebo
Number of subjects: 0
Study: 6354663

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 30705390

Group type: EXPERIMENTAL
Intervention: Support intervention (physicians endorsing, offering, and facilitating a referral to a weight loss programme)
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Advice (recommending weight loss)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Support intervention
Number of subjects: 1882
Study: 28193288

Group type: EXPERIMENTAL
Intervention: Accreditation in 2016
Number of subjects: 2211

Group type: COMPARATOR
Intervention: Accreditation in 2018
Number of subjects: 2211
Study: 27358413

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (SSBs) >5 servings/week
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Artificially sweetened beverages >5 servings/week
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Natural fruit juices >5 servings/week
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Bottled fruit juices >5 servings/week
Number of subjects: 1868

Group type: COMPARATOR
Intervention: Sugar-sweetened beverages (SSBs) 1-5 servings/week
Number of subjects: 1868

Group type: COMPARATOR
Intervention: Artificially sweetened beverages 1-5 servings/week
Number of subjects: 1868
Study: 25084699

Group type: EXPERIMENTAL
Intervention: Rural sanitation intervention under the Total Sanitation Campaign
Number of subjects: 100
Study: 22036910

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg/day
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1085
Study: 18922689

Group type: EXPERIMENTAL
Intervention: Laparoscopy assisted distal gastrectomy (LADG)
Number of subjects: 951

Group type: COMPARATOR
Intervention: Open distal gastrectomy (ODG)
Number of subjects: 951
Study: 17197028

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Travoprost
Number of subjects: 40
Study: 15860533

Group type: EXPERIMENTAL
Intervention: Incremental cycling exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Constant cycling exercise
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: One-legged knee-extensor exercise
Number of subjects: 18
Study: 11988191

Group type: EXPERIMENTAL
Intervention: Access AccuTnI assay (cTnI)
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: AxSym assay (cTnI)
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Elecsys 3rd generation assay (cTnI)
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 1763

Group type: EXPERIMENTAL
Intervention: Nonelevated cTroponin levels
Number of subjects: 1763
Study: 9921986

Group type: EXPERIMENTAL
Intervention: Initial biopsy with isolated high grade prostatic intraepithelial neoplasia (PIN)
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Initial biopsy with borderline lesions
Number of subjects: 1824

Group type: EXPERIMENTAL
Intervention: Overall prostate carcinoma detection
Number of subjects: 1824
Study: 7551939

Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide and cisplatin (MIC) with radical radiotherapy
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Mitomycin, ifosfamide and cisplatin (MIC) with palliative care
Number of subjects: 317

Group type: COMPARATOR
Intervention: Mitomycin, ifosfamide and cisplatin (MIC)
Number of subjects: 317
Study: 1720487

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 549

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 549
Study: 7137834

Group type: EXPERIMENTAL
Intervention: Peritoneal lavage for 72 hours
Number of subjects: 87

Group type: COMPARATOR
Intervention: No lavage
Number of subjects: 87
Study: 30807583

Group type: EXPERIMENTAL
Intervention: Sphincter Control Training (SCT) with masturbation aid device (Flip Zero)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sphincter Control Training (SCT) without masturbation aid device
Number of subjects: 35
Study: 28296722

Group type: EXPERIMENTAL
Intervention: Personalized addition PALs
Number of subjects: 211

Group type: COMPARATOR
Intervention: +2.00 addition PALs
Number of subjects: 211

Group type: COMPARATOR
Intervention: Single vision lenses (SVLs)
Number of subjects: 211
Study: 26675247

Group type: EXPERIMENTAL
Intervention: Craigslist (CL)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Print Newspapers (PN)
Number of subjects: 134
Study: 23354927

Group type: EXPERIMENTAL
Intervention: LAGB (gastric banding)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Hypocaloric diet
Number of subjects: 24
Study: 22022472

Group type: EXPERIMENTAL
Intervention: 10% protein diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 15% protein diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 25% protein diet
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10% protein breakfast
Number of subjects: 22